High materiality7/10
Faeth Therapeutics initiated with a Buy at Guggenheim
Why it may matterVerify against the original reporting
Strong upside from Buy rating and high target.
Public signal · 1-minute delayed
Signal brief
Source-backed market context you can read and share without an account.
AI summary
What happened, with direct paths to the underlying reporting
Guggenheim initiates Faeth Therapeutics with Buy; target $70; price $35.37.
- Guggenheim initiates Faeth Therapeutics with Buy; target $70; price $35.37
Key facts
- 01
Target: $70
- 02
Posted price: $35.37
- 03
Analyst firm: Guggenheim
- 04
Analyst: Brad Canino
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.